Call Options

7 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2024

May 15, 2024

BUY
$11.27 - $13.53 $1.71 Million - $2.05 Million
151,800 Added 55.52%
425,200 $5.08 Million
Q4 2023

Feb 14, 2024

BUY
$8.77 - $10.85 $107,871 - $133,455
12,300 Added 4.71%
273,400 $2.96 Million
Q3 2023

Nov 14, 2023

BUY
$9.59 - $11.35 $469,910 - $556,150
49,000 Added 23.1%
261,100 $2.57 Million
Q2 2023

Aug 14, 2023

SELL
$9.02 - $10.29 $45,100 - $51,449
-5,000 Reduced 2.3%
212,100 $2.12 Million
Q1 2023

May 15, 2023

SELL
$9.2 - $12.26 $823,399 - $1.1 Million
-89,500 Reduced 29.19%
217,100 $2.09 Million
Q4 2022

Feb 14, 2023

SELL
$8.72 - $11.56 $81,619 - $108,201
-9,360 Reduced 2.96%
306,600 $3.41 Million
Q3 2022

Nov 14, 2022

SELL
$8.48 - $11.13 $183,168 - $240,408
-21,600 Reduced 6.4%
315,960 $2.69 Million

Others Institutions Holding VTRS

About Viatris Inc


  • Ticker VTRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 1,212,669,952
  • Market Cap $12.9B
  • Description
  • Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, i...
More about VTRS
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.